JPH0971523A - Tablet quickly disintegrating in oral cavity - Google Patents

Tablet quickly disintegrating in oral cavity

Info

Publication number
JPH0971523A
JPH0971523A JP26458395A JP26458395A JPH0971523A JP H0971523 A JPH0971523 A JP H0971523A JP 26458395 A JP26458395 A JP 26458395A JP 26458395 A JP26458395 A JP 26458395A JP H0971523 A JPH0971523 A JP H0971523A
Authority
JP
Japan
Prior art keywords
tablet
low
oral cavity
crystalline cellulose
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP26458395A
Other languages
Japanese (ja)
Inventor
Yoshiteru Watanabe
善照 渡辺
Miyuki Kiriyama
美由紀 桐山
Yoshiko Zama
喜子 座間
Keiichi Koizumi
桂一 小泉
Mitsuo Matsumoto
光雄 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIYUUKAKUSAN KK
Original Assignee
RIYUUKAKUSAN KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIYUUKAKUSAN KK filed Critical RIYUUKAKUSAN KK
Priority to JP26458395A priority Critical patent/JPH0971523A/en
Publication of JPH0971523A publication Critical patent/JPH0971523A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Abstract

PROBLEM TO BE SOLVED: To obtain a tablet quickly disintegrating in the oral cavity with saliva (or a small amount of water) within about several tens seconds to enable the taking of the tablet by an aged man lacking chewing power or at a place free from available water. SOLUTION: This tablet quickly disintegrating in the oral cavity with saliva (or a small amount of water) (quickly disintegrating tablet) is composed of a composition produced by mixing a hydroxypropyl cellulose having low degree of substitution as a disintegrant, a crystalline cellulose as a diluent and a lubricant. The compounding ratio of the low-substitution degree hydroxyproply cellulose to the crystalline cellulose is 1:(2.3-9).

Description

【発明の詳細な説明】Detailed Description of the Invention

【０００１】[0001]

【発明の属する技術分野】本発明は、口腔内の唾液又は
少量の水により噛まずにただちに崩壊してそのまま又は
水にて服用できる口腔内において崩壊性の速い錠剤（以
下、速崩壊性錠剤という）の組成物および製法を提供す
る技術分野に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a rapidly disintegrating tablet in the oral cavity (hereinafter referred to as a fast disintegrating tablet) which can be taken immediately without being chewed by saliva or a small amount of water in the oral cavity and can be taken as it is or with water. The present invention relates to the technical field of providing a composition and a production method thereof.

【０００２】[0002]

【従来の技術】水無しで服用できる製剤としてはチュア
ブル錠が、胃腸薬などとして市販されている。これは服
用時に水などの飲料を不要とし、必要なときにすぐに口
腔内で噛み砕いて服用できるというものである。また錠
剤型で口腔内で噛まずに速やかに崩壊して、錠剤の嚥下
を容易にする製剤は見当たらない。2. Description of the Related Art Chewable tablets are commercially available as a gastrointestinal drug and the like as a formulation which can be taken without water. This means that no drink such as water is required when taking the drug, and when necessary, it can be chewed in the oral cavity and taken immediately. In addition, there is no formulation in tablet form that disintegrates rapidly without chewing in the oral cavity and facilitates swallowing of tablets.

【発明が解決しようとする課題】[Problems to be Solved by the Invention]

【０００３】上述のチュアブル錠を服用する時に噛み砕
くことを必要とすることは、老人などの歯の弱い人たち
にとっては、不便である。また嚥下力の弱い患者にとっ
て口腔内で速やかに崩壊して服用できる錠剤は有用であ
る。The need to chew when taking the chewable tablets described above is inconvenient for people with weak teeth, such as the elderly. Tablets that can be rapidly disintegrated and taken in the oral cavity are useful for patients with weak swallowing power.

【０００４】本発明は、かかる観点からなされたもので
あり、口腔内で唾液又は少量の水により数十秒程度で速
やかに崩壊して嚥下を容易にする錠剤を提供することを
課題とする。The present invention has been made from such a point of view, and an object of the present invention is to provide a tablet which is rapidly disintegrated by saliva or a small amount of water in the oral cavity in about several tens of seconds to facilitate swallowing.

【０００５】本発明の速崩壊性錠剤を必要とする状況と
しては、水の無い場面での錠剤の服用を必要とする薬剤
で、例えば乗り物酔止め薬がある。また、従来の錠剤型
では嚥下困難な患者は錠剤を砕いて服用する必要があっ
た。本発明の速崩壊性錠剤は口腔内で速く崩壊し、嚥下
困難な患者の錠剤の服用に有用である。特に脳血管障害
などで嚥下困難な患者や寝たきりの高齢患者に速崩錠は
有用であり、薬物としては高血圧症用薬、脳循環代謝改
善薬などがある。A situation in which the rapidly disintegrating tablet of the present invention is required is a drug which requires taking the tablet in a waterless situation, for example, a motion sickness drug. Further, a patient who has difficulty swallowing with the conventional tablet type needs to crush the tablet and take it. The rapidly disintegrating tablet of the present invention disintegrates rapidly in the oral cavity and is useful for taking tablets for patients who have difficulty swallowing. In particular, quick-disintegrating tablets are useful for patients who have difficulty swallowing due to cerebrovascular disorder or bedridden elderly patients, and examples of such drugs include drugs for hypertension and drugs for improving cerebral circulation metabolism.

【課題を解決するための手段】[Means for Solving the Problems]

【０００６】本発明者は、上記課題を解決するために、
錠剤の賦形剤および崩壊剤を以下の組成とした。In order to solve the above problems, the present inventor has
The tablet excipient and disintegrant had the following composition.

【０００７】すなわち本発明の速崩壊性錠剤は、崩壊剤
とする低置換度ヒドロキシプロピルセルロースを１とし
た時に賦形剤として結晶セルロースを２．３から９の割
合の配合比で混合し、滑沢剤を配合・混合し、更に必要
があれば着色剤などを配合・混合し打錠することにより
錠剤を圧縮成型することを特徴とする。That is, in the rapidly disintegrating tablet of the present invention, when low-substituted hydroxypropylcellulose as a disintegrating agent is set to 1, crystalline cellulose is mixed as an excipient at a compounding ratio of 2.3 to 9, and a smooth mixture is prepared. The tablet is compression-molded by blending and mixing a lubricant, and further blending and mixing a colorant and the like and tableting if necessary.

【０００８】また本発明では速崩壊性錠剤に含有させる
薬物としては、乗り物酔いの治療に有効な鎮暈および鎮
吐作用を有する薬物である塩酸メクリジンが有用であ
る。他に本発明で対象とする乗り物酔いの治療に有効な
鎮暈および鎮吐作用を有する薬物としては前述の塩酸メ
クリジン以外の具体例としては、ジメンヒドリナート、
チエルペラジン、サリチル酸ジフェンヒドラミン＋ジプ
ロフィリン、プロメタジンテオクレートなどが挙げられ
る。高血圧症用薬としてはカプトプリル、シラザプリ
ル、マレイン酸エナラプリル、リシノプリルなどが挙げ
られ、脳循環代謝改善薬としてはシンナリジン、ビンポ
セチン、フマル酸ブロビンカミン、ペントキシフィリ
ン、マレイン酸シネパジド、トラピジル、塩酸ニカルジ
ピン、塩酸フルナリジン、塩酸メクロフェノキサート、
酒石酸イフェンプロジルなどが挙げられる。In the present invention, as a drug to be contained in the fast disintegrating tablet, meclizine hydrochloride, which is a drug effective for treating motion sickness and having an anti-nausea and anti-emetic action, is useful. In addition to the above-mentioned meclizine hydrochloride as a drug having an effective antispasmodic and antiemetic action for the treatment of motion sickness targeted by the present invention, dimenhydrinate,
Examples thereof include thierperazine, diphenhydramine salicylate + diprophylline, and promethazine theocrate. Drugs for hypertension include captopril, cilazapril, enalapril maleate, lisinopril, etc.As cerebral circulatory metabolism improving agents, cinnarizine, vinpocetine, brovincamin fumarate, pentoxifylline, cinepazide maleate, trapidil, nicardipine hydrochloride, flunarizine hydrochloride. , Meclofenoxate hydrochloride,
Examples include ifenprodil tartrate.

【０００９】以下、本発明を説明する。The present invention will be described below.

【００１０】＜１＞本発明の速崩壊性錠剤の製法 １）組成物 本発明では一般的に使用される下記の賦形剤、崩壊剤を
使用して速崩壊性錠剤を作ることを特徴としている。 結晶セルロース（賦形剤） （旭化成工業（株）製アビセルＰＨ−１０２、粒子径１
００μｍ） 低置換度ヒドロキシプロピルセルロース（崩壊剤） （信越化学工業（株）製Ｌ−ＨＰＣ、粒子径１６０μ
ｍ、日本薬局方１２局収載）<1> Method for Producing Rapidly Disintegrating Tablet of the Present Invention 1) Composition In the present invention, a rapidly disintegrating tablet is produced by using the following excipients and disintegrating agents which are generally used. There is. Crystalline cellulose (excipient) (Avicel PH-102 manufactured by Asahi Kasei Corporation, particle size 1)
00 μm) Low-substituted hydroxypropylcellulose (disintegrant) (Shin-Etsu Chemical Co., Ltd. L-HPC, particle size 160 μm)
m, listed in 12 Japanese Pharmacopoeia)

【００１１】２）本発明の速崩壊性錠剤の配合割合 薬物を含有しない速崩壊性錠剤 ・ステアリン酸マグネシウム（滑沢剤：和光純薬工業
（株）製ＭＳ、粒子径７０μｍ）１％、低置換度ヒドロ
キシプロピルセルロースと結晶セルロースの配合比を
１：２．３から１：９で配合・混合したもの各９９％上
記混合物を打錠用剤とする。2) Blending ratio of the rapidly disintegrating tablet of the present invention: Fast disintegrating tablet containing no drug Magnesium stearate (lubricant: MS manufactured by Wako Pure Chemical Industries, Ltd., particle size 70 μm) 1%, low Degree of substitution Hydroxypropyl cellulose and crystalline cellulose are compounded and mixed at a compounding ratio of 1: 2.3 to 1: 9, 99% each. The above mixture is used as a tableting agent.

【００１２】薬物（塩酸メクリジン）含有速崩壊性錠
剤 ・塩酸メクリジン（鎮暈・鎮吐剤：日本バルク薬品製、
分子量４８１．８９、融点２１７℃（分解））１０％、
ステアリン酸マグネシウム１％、低置換度ヒドロキシプ
ロピルセルロースと結晶セルロースの配合比を１：４混
合したもの８９％ 上記混合物を打錠用剤とする。Rapidly disintegrating tablet containing drug (meclizine hydrochloride) Meclizine hydrochloride (anxiety / antiemetic: manufactured by Nippon Bulk Chemical Co., Ltd.,
Molecular weight 481.89, melting point 217 ° C (decomposition) 10%,
Magnesium stearate 1%, low-substituted hydroxypropyl cellulose and crystalline cellulose mixed at a mixing ratio of 1: 4 89% The above mixture is used as a tableting composition.

【００１３】３）本発明の速崩壊性錠剤の打錠条件 下記の条件で、錠剤を製造した。一般に成型荷重をかけ
るほど錠剤の硬度が上がり、崩壊しにくくなるとされて
いる。しかし本発明の速崩壊性錠剤は１００〜３００ｋ
ｇｆの成型荷重（以下、打錠圧という）で、硬度のある
速崩壊性錠剤を得ることができた。 装 置 ：Ｎ−２０Ｅ型両圧式粉末打錠機（岡田精工
（株）製）杵直径８．０ｍｍ、曲率半径１０Ｒ 錠剤重量：２００ｍｇ 打錠圧 ：１００〜３００ｋｇｆ3) Tableting Conditions for the Rapidly Disintegrating Tablet of the Present Invention Tablets were produced under the following conditions. Generally, it is said that the more the molding load is applied, the higher the hardness of the tablet and the more difficult it becomes to disintegrate. However, the rapidly disintegrating tablet of the present invention is 100 to 300 k
With a molding load of gf (hereinafter referred to as tableting pressure), a rapidly disintegrating tablet having hardness could be obtained. Device: N-20E double-pressure powder tableting machine (Okada Seiko Co., Ltd.), punch diameter 8.0 mm, radius of curvature 10R Tablet weight: 200 mg Tableting pressure: 100-300 kgf

【００１４】＜２＞本発明の速崩壊性錠剤の効果を測定
するための条件 １）錠剤硬度測定 錠剤はある程度かたさ（以下、硬度と言う）がないと錠
剤の原型をとどめず、適正な打錠圧で硬度がありながら
速崩壊性の錠剤であることが必須条件である。この為に
硬度を測定した。後述する市販品素錠の測定では１３〜
１５Ｋｇの硬度であった。本発明の速崩壊性の錠剤も同
様な硬度を得た。 半自動硬度計（ＴＳ−５０Ｎ型、岡田精工（株）製） 圧縮破壊に要する応力を測定し、これを硬度（ｋｇ）と
する。<2> Conditions for measuring the effect of the rapidly disintegrating tablet of the present invention 1) Tablet hardness measurement Unless the tablet has a certain degree of hardness (hereinafter referred to as hardness), the tablet prototype cannot be retained and the tablet can be pressed properly. It is an essential condition that the tablet has hardness at tableting pressure but is rapidly disintegrating. For this purpose the hardness was measured. In the measurement of commercially available plain tablets described later,
The hardness was 15 kg. The rapidly disintegrating tablets of the present invention also obtained similar hardness. Semi-automatic hardness meter (TS-50N type, manufactured by Okada Seiko Co., Ltd.) The stress required for compressive fracture is measured, and this is defined as the hardness (kg).

【００１５】２）錠剤の崩壊性 速崩壊性錠剤の崩壊性を下記の代用試験により測定し
た。本試験の結果は実際の口腔内での結果と相関性があ
る。本発明の速崩壊性錠剤は実施例で示すようにすべて
７４秒以内で崩壊した。小型シャーレ中の水に錠剤を全
浸または半浸させる。口腔内での崩壊は、舌の動きが加
わるため、この小型シャーレーに弱い振とうを加えて崩
壊時間を測定した。 振とう器 ＳＡ−３１型（ヤマトサイエンテフィック社
製）振幅距離、４ｃｍ 振とう回数：４０回／分＝１回／１．５秒（最小設定
値）2) Disintegration property of tablets The disintegration property of fast disintegrating tablets was measured by the following substitute test. The results of this study correlate with the actual oral results. All the rapidly disintegrating tablets of the present invention disintegrated within 74 seconds as shown in the examples. Fully or half soak the tablets in water in a small petri dish. As for the disintegration in the oral cavity, since the movement of the tongue was added, weak shaking was added to this small Petri dish to measure the disintegration time. Shaker SA-31 type (manufactured by Yamato Scientific Co., Ltd.) Amplitude distance, 4 cm Shaking frequency: 40 times / min = 1 time / 1.5 seconds (minimum setting value)

【００１６】本発明の速崩壊性錠剤（重量２００ｍｇ、
直径８ｍｍ）とほぼ同じ大きさの市販素錠Ａ（重量２０
０ｍｇ、直径８ｍｍ）とＢ（重量２８０ｍｇ、直径９ｍ
ｍを用いて、上記の条件で試験した結果を表１に示す。
これらの市販素錠は速崩壊性錠剤と言えないことは明き
らかであり、本発明の速崩壊性錠剤は市販素錠とは大い
に異なっている。 The fast disintegrating tablet of the present invention (weight: 200 mg,
Commercial uncoated tablet A (weight 20 mm), which is almost the same size as the diameter 8 mm
0 mg, diameter 8 mm) and B (weight 280 mg, diameter 9 m)
Table 1 shows the results of tests conducted under the above conditions using m.
It is clear that these commercially available plain tablets cannot be said to be rapidly disintegrating tablets, and the rapidly disintegrating tablet of the present invention is very different from the commercially available plain tablets.

【００１７】[0017]

【実施例】以下に本発明の実施例を具体的に説明する。EXAMPLES Examples of the present invention will be specifically described below.

【００１８】[0018]

【実施例１】低置換度ヒドロキシプロピルセルロースと
結晶セルロースの配合比３：７（低置換度ヒドロキシプ
ロピルセルロースを１とすると１：２．３となる）。 成 分 量 結晶セルロース ６９．３％ 低置換度ヒドロキシプロピルセルロース ２９．７％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表２
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 [Example 1] Mixing ratio of low-substituted hydroxypropyl cellulose and crystalline cellulose 3: 7 (1: 2.3 for low-substituted hydroxypropyl cellulose). Ingredients Crystalline cellulose 69.3% Low-substituted hydroxypropylcellulose 29.7% Magnesium stearate 1.0% The above powders were uniformly mixed and then compressed with a tableting machine. Table 2
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００１９】[0019]

【実施例２】低置換度ヒドロキシプロピルセルロースと
結晶セルロースの配合比１：３．５ 成 分 量 結晶セルロース ７７．０％ 低置換度ヒドロキシプロピルセルロース ２２．０％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表３
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 [Example 2] Mixing ratio of low-substituted hydroxypropyl cellulose and crystalline cellulose 1: 3.5 Component amount Crystalline cellulose 77.0% Low-substituted hydroxypropyl cellulose 22.0% Magnesium stearate 1.0% The above powder Were uniformly mixed and then compressed with a tableting machine. Table 3
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００２０】[0020]

【実施例３】低置換度ヒドロキシプロピルセルロースと
結晶セルロース配合比１：４ 成 分 量 結晶セルロース ７９．２％ 低置換度ヒドロキシプロピルセルロース １９．８％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表４
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 Example 3 Low-Substitution Hydroxypropyl Cellulose / Crystalline Cellulose Blending Ratio 1: 4 Content Crystalline Cellulose 79.2% Low-Substitutional Hydroxypropyl Cellulose 19.8% Magnesium Stearate 1.0% The above powder is uniformly mixed. After mixing, it was compressed with a tablet machine. Table 4
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００２１】[0021]

【実施例４】低置換度ヒドロキシプロピルセルロースと
結晶セルロースの配合比１：８ 成 分 量 結晶セルロース ８８．０％ 低置換度ヒドロキシプロピルセルロース １１．０％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表５
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 [Example 4] Mixing ratio of low-substituted hydroxypropyl cellulose and crystalline cellulose 1: 8 Component amount Crystalline cellulose 88.0% Low-substituted hydroxypropyl cellulose 11.0% Magnesium stearate 1.0% The above powder was homogenized. After being mixed with, the mixture was compressed with a tableting machine. Table 5
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００２２】[0022]

【実施例５】低置換度ヒドロキシプロピルセルロースと
結晶セルロースの配合比１：９ 成 分 量 結晶セルロース ８９．１％ 低置換度ヒドロキシプロピルセルロース ９．９％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表６
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 [Example 5] Mixing ratio of low-substituted hydroxypropyl cellulose and crystalline cellulose 1: 9 Component amount Crystalline cellulose 89.1% Low-substituted hydroxypropyl cellulose 9.9% Magnesium stearate 1.0% The above powder was homogenized. After being mixed with, the mixture was compressed with a tableting machine. Table 6
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００２３】[0023]

【実施例６】 塩酸メクリジンを加えた処方。 塩酸メクリジン１０％と低置換度ヒドロキシプロピルセ
ルロースと結晶セルロースの配合比３：７（低置換度ヒ
ドロキシプロピルセルロースを１とすると１：２．３と
なる）。 成 分 量 塩酸メクリジン １０．０％ 結晶セルロース ６２．３％ 低置換度ヒドロキシプロピルセルロース ２６．７％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表７
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 Example 6 Formulation with addition of meclizine hydrochloride. Mixing ratio of meclizine hydrochloride 10%, low-substituted hydroxypropyl cellulose and crystalline cellulose 3: 7 (1: 2.3 for low-substituted hydroxypropyl cellulose). Ingredients Meclizine hydrochloride 10.0% Crystalline cellulose 62.3% Low-substituted hydroxypropylcellulose 26.7% Magnesium stearate 1.0% The above powders were uniformly mixed and then compressed with a tableting machine. Table 7
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００２４】[0024]

【実施例７】 塩酸メクリジンを加えた処方。 塩酸メクリジン１０％と低置換度ヒドロキシプロピルセ
ルロースと結晶セルロースの配合比１：４ 成 分 量 塩酸メクリジン １０．０％ 結晶セルロース ７１．２％ 低置換度ヒドロキシプロピルセルロース １７．８％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表８
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 Example 7 Formulation with the addition of meclizine hydrochloride. Mixing ratio of meclizine hydrochloride 10%, low-substituted hydroxypropyl cellulose and crystalline cellulose 1: 4 Component amount Meclizine hydrochloride 10.0% Crystalline cellulose 71.2% Low-substituted hydroxypropyl cellulose 17.8% Magnesium stearate 1. 0% The above powders were uniformly mixed and then compressed with a tableting machine. Table 8
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００２５】[0025]

【実施例８】 塩酸メクリジンを加えた処方。 塩酸メクリジン１０％と低置換度ヒドロキシプロピルセ
ルロースと結晶セルロース配合比１：９ 成分 量 塩酸メクリジン １０．０％ 結晶セルロース ８０．１％ 低置換度ヒドロキシプロピルセルロース ８．９％ ステアリン酸マグネシウム １．０％ 上記粉末を均一に混合した後、打錠機で圧縮した。表９
に示したように良好な崩壊時間と打錠圧、硬度の関係を
得た。 Example 8 Formulation with addition of meclizine hydrochloride. Meklizine hydrochloride 10%, low-substituted hydroxypropylcellulose and crystalline cellulose Blending ratio 1: 9 Component amount Meclizine hydrochloride 10.0% Crystalline cellulose 80.1% Low-substituted hydroxypropylcellulose 8.9% Magnesium stearate 1.0% The above powders were uniformly mixed and then compressed with a tableting machine. Table 9
As shown in Fig. 3, a good relationship between the disintegration time, the tableting pressure and the hardness was obtained.

【００２６】[0026]

【発明の効果】本発明の速崩壊性錠剤は、小型シャーレ
による崩壊試験で崩壊時間が７０秒以下で、口腔内で唾
液（少量の水）により数十秒程度で速やかに崩壊する錠
剤を提供することを可能とする。その結果、嚥下力の弱
い老人が服用する錠剤、水の無い場面での錠剤の服用を
可能にするものである。EFFECTS OF THE INVENTION The fast disintegrating tablet of the present invention provides a tablet that disintegrates in a disintegration test using a small petri dish for 70 seconds or less and rapidly disintegrates in the oral cavity with saliva (a small amount of water) in about tens of seconds. It is possible to do. As a result, it enables tablets to be taken by an elderly person having a weak swallowing power and tablets without water.

Claims (1)

【特許請求の範囲】[Claims] 【請求項１】 組成が薬物、結晶セルロース、低置換度
ヒドロキシプロピルセルロース、滑沢剤を混合した物か
らなり、低置換度ヒドロキシプロピルセルロースと結晶
セルロースの配合比が低置換度ヒドロキシプロピルセル
ロースを１として１：２．３から１：９で配合・混合し
たものを圧縮成型することよりなる口腔内で崩壊性の速
い錠剤。1. A composition comprising a mixture of a drug, crystalline cellulose, low-substituted hydroxypropyl cellulose and a lubricant, wherein the compounding ratio of low-substituted hydroxypropyl cellulose and crystalline cellulose is 1 to 1 of low-substituted hydroxypropyl cellulose. A tablet rapidly disintegrating in the oral cavity, which is obtained by compressing and molding a mixture of 1: 2.3 to 1: 9.
JP26458395A 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity Pending JPH0971523A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP26458395A JPH0971523A (en) 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26458395A JPH0971523A (en) 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity

Publications (1)

Publication Number Publication Date
JPH0971523A true JPH0971523A (en) 1997-03-18

Family

ID=17405316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26458395A Pending JPH0971523A (en) 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity

Country Status (1)

Country Link
JP (1) JPH0971523A (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053798A1 (en) * 1997-05-27 1998-12-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
WO1998042310A3 (en) * 1997-03-22 1998-12-23 Boots Co Plc Fast release compressed tablet of flurbiprofen
JPH1143429A (en) * 1997-05-27 1999-02-16 Takeda Chem Ind Ltd Solid preparation
WO1999018936A1 (en) * 1997-10-09 1999-04-22 Ssp Co., Ltd. Quickly soluble solid preparations
FR2784895A1 (en) * 1998-10-23 2000-04-28 Gattefosse Ets Sa Tablets have the active material coated with a polyhydroxy ester lipid then bound with a hydroxy propyl cellulose ether to mask the flavor and give immediate liberation when crunched
JP2001342128A (en) * 2000-06-01 2001-12-11 Sato Pharmaceutical Co Ltd Tablet having hardness stabilized against humidity and disintegrating in oral cavity
US6559134B2 (en) 2000-03-17 2003-05-06 Shin-Etsu Chemical Co., Ltd. Solid preparation containing low-substituted hydroxypropyl cellulose and production process thereof
FR2845914A1 (en) * 2002-10-18 2004-04-23 Schwarz Pharma Lab Antiemetic tablet that disintegrates rapidly in the mouth, useful for treating nausea and vomiting, includes powdered agent with both disintegrating and binding properties
JP2005162613A (en) * 2002-06-14 2005-06-23 Nippon Boehringer Ingelheim Co Ltd Brotizolam-containing tablet
US7070805B2 (en) 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
EP1736144A2 (en) 1998-05-18 2006-12-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
CN100356911C (en) * 2002-09-09 2007-12-26 爱诗爱诗制药株式会社 Compressed-shaping formulation for hypnosis
JP2008509089A (en) * 2004-06-17 2008-03-27 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン Ready-to-drink tablets made by direct compression of memantine or neramexane
WO2008120548A2 (en) 2007-03-13 2008-10-09 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
WO2009022670A1 (en) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited Quickly disintegrating tablet
JP2009196940A (en) * 2008-02-22 2009-09-03 Takada Seiyaku Kk Tablet quickly disintegrating in oral cavity and its production method
JP2010505791A (en) * 2006-10-06 2010-02-25 エフ．ホフマン−ラ ロシュ アーゲー Capecitabine pediatric tablets
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP2010053047A (en) * 2008-08-26 2010-03-11 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with good elution property and orally disintegrable tablet
JP4562797B1 (en) * 2009-05-29 2010-10-13 マイラン製薬株式会社 Orally disintegrating tablets containing precipitated calcium carbonate as an active ingredient
WO2012018056A1 (en) * 2010-08-03 2012-02-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Compressed composition
JP2013173802A (en) * 2013-06-13 2013-09-05 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2015061828A (en) * 2013-08-23 2015-04-02 第一三共株式会社 Intraorally disintegrable tablet and method for producing the same
JP2015110663A (en) * 2015-03-11 2015-06-18 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2016183195A (en) * 2016-07-25 2016-10-20 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2017141299A (en) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet
JP2018168185A (en) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition and orally disintegrable tablet with excellent elution
JP2019203031A (en) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042310A3 (en) * 1997-03-22 1998-12-23 Boots Co Plc Fast release compressed tablet of flurbiprofen
JPH1143429A (en) * 1997-05-27 1999-02-16 Takeda Chem Ind Ltd Solid preparation
WO1998053798A1 (en) * 1997-05-27 1998-12-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
US6586004B2 (en) 1997-05-27 2003-07-01 Takeda Chemical Industries, Ltd. Solid preparation
US6299904B1 (en) 1997-05-27 2001-10-09 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
US6455053B1 (en) 1997-10-09 2002-09-24 Ssp Co., Ltd. Quickly soluble solid preparations
WO1999018936A1 (en) * 1997-10-09 1999-04-22 Ssp Co., Ltd. Quickly soluble solid preparations
US7431942B2 (en) 1998-05-18 2008-10-07 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
EP2263660A2 (en) 1998-05-18 2010-12-22 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
EP1736144A2 (en) 1998-05-18 2006-12-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7875292B2 (en) 1998-05-18 2011-01-25 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US9901546B2 (en) 1998-05-18 2018-02-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7070805B2 (en) 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US7399485B1 (en) 1998-07-28 2008-07-15 Takeda Pharmaceutical Company Limited Rapidly Disintegrable solid preparation
WO2000024385A1 (en) * 1998-10-23 2000-05-04 Gattefosse S.A. Tablet for crunching with masked taste and instant release of active principle and method for making same
FR2784895A1 (en) * 1998-10-23 2000-04-28 Gattefosse Ets Sa Tablets have the active material coated with a polyhydroxy ester lipid then bound with a hydroxy propyl cellulose ether to mask the flavor and give immediate liberation when crunched
US6559134B2 (en) 2000-03-17 2003-05-06 Shin-Etsu Chemical Co., Ltd. Solid preparation containing low-substituted hydroxypropyl cellulose and production process thereof
JP2001342128A (en) * 2000-06-01 2001-12-11 Sato Pharmaceutical Co Ltd Tablet having hardness stabilized against humidity and disintegrating in oral cavity
JP2005162613A (en) * 2002-06-14 2005-06-23 Nippon Boehringer Ingelheim Co Ltd Brotizolam-containing tablet
JP4605977B2 (en) * 2002-06-14 2011-01-05 日本ベーリンガーインゲルハイム株式会社 Tablets containing brotizolam
CN100356911C (en) * 2002-09-09 2007-12-26 爱诗爱诗制药株式会社 Compressed-shaping formulation for hypnosis
FR2845914A1 (en) * 2002-10-18 2004-04-23 Schwarz Pharma Lab Antiemetic tablet that disintegrates rapidly in the mouth, useful for treating nausea and vomiting, includes powdered agent with both disintegrating and binding properties
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP2008509089A (en) * 2004-06-17 2008-03-27 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン Ready-to-drink tablets made by direct compression of memantine or neramexane
JP2010505791A (en) * 2006-10-06 2010-02-25 エフ．ホフマン−ラ ロシュ アーゲー Capecitabine pediatric tablets
US8778392B2 (en) 2007-03-13 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
US9980915B2 (en) 2007-03-13 2018-05-29 Sumitomo Dainippon Pharma Co., Ltd. Oral disintegrating tablet
WO2008120548A2 (en) 2007-03-13 2008-10-09 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
WO2009022670A1 (en) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited Quickly disintegrating tablet
JP2009196940A (en) * 2008-02-22 2009-09-03 Takada Seiyaku Kk Tablet quickly disintegrating in oral cavity and its production method
JP2010053047A (en) * 2008-08-26 2010-03-11 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with good elution property and orally disintegrable tablet
WO2010137716A1 (en) * 2009-05-29 2010-12-02 マイラン製薬株式会社 Orally disintegrating tablet which contains precipitated calcium carbonate as active ingredient
JP2011006377A (en) * 2009-05-29 2011-01-13 Mylan Seiyaku Ltd Orally disintegrable tablet which contains precipitated calcium carbonate as active ingredient
JP4562797B1 (en) * 2009-05-29 2010-10-13 マイラン製薬株式会社 Orally disintegrating tablets containing precipitated calcium carbonate as an active ingredient
JPWO2012018056A1 (en) * 2010-08-03 2013-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Compressed composition
WO2012018056A1 (en) * 2010-08-03 2012-02-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Compressed composition
JP2013173802A (en) * 2013-06-13 2013-09-05 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2015061828A (en) * 2013-08-23 2015-04-02 第一三共株式会社 Intraorally disintegrable tablet and method for producing the same
JP2015110663A (en) * 2015-03-11 2015-06-18 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2016183195A (en) * 2016-07-25 2016-10-20 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2017141299A (en) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet
JP2018168185A (en) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition and orally disintegrable tablet with excellent elution
JP2019203031A (en) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet
JP2021113237A (en) * 2019-09-06 2021-08-05 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet

Similar Documents

Publication Publication Date Title
JPH0971523A (en) Tablet quickly disintegrating in oral cavity
KR100826819B1 (en) Orally disintegrating tablets and process for obtaining them
US6696085B2 (en) Use of an acrylic type polymer as disintegrating agent
US20100260840A1 (en) Orodispersible pharmaceutical composition of agomelatine
JP2011225588A (en) Composition disintegrable in oral cavity, and pharmaceutical preparation disintegrable in oral cavity
US20120076856A1 (en) Orodispersible pharmaceutical composition of perindopril
JPH10182436A (en) Solid medicinal preparation
HUE030609T2 (en) New pharmaceutical formulations useful in the treatment of insomnia
JP2000119175A (en) Intraoral rapid disintegrative solid preparation
US20030147947A1 (en) Orodispersible solid pharmaceutical form
AU2004262964A1 (en) Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof
JP3884056B1 (en) Method for producing intraoral rapidly disintegrating tablet
KR20070119654A (en) Pharmaceutical composition
JPWO2003103713A1 (en) Quick disintegrating tablet and method for producing the same
KR100613550B1 (en) Orodispersible pharmaceutical composition comprising ivabradine
JP2003176242A (en) Quickly disintegrable compression-molded material and method for producing the same
JP2007197438A (en) Quickly disintegrating tablet in oral cavity
JP2010241760A (en) Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same
JP6257642B2 (en) Orally dispersible tablets obtained by compression molding
Raj Formulation and In-vitro evaluation of Voglibose Dispersible tablets
KR100762598B1 (en) Orodispersible pharmaceutical composition of an antithrombotic compound
Mishra et al. Formulation and evaluation of mouth dissolving tablets of carvedilol
JP6341196B2 (en) Solid preparation
JP3967767B1 (en) Method for producing intraoral rapidly disintegrating tablet
JP5490691B2 (en) Fast disintegrating preparation containing calcium carbonate

Legal Events

Date Code Title Description
A02 Decision of refusal

Effective date: 20040210

Free format text: JAPANESE INTERMEDIATE CODE: A02